Dr Cherie Stayner
| Position | Research Fellow |
|---|---|
| Departments | Department of Medicine (Dunedin), Department of Pathology (Dunedin) |
| Qualifications | BSc(Hons)(Massey) PhD(Otago) |
| Research summary | Molecular basis of polycystic kidney disease |
Research
My main research interest is the study of a human disease called Autosomal Dominant Polycystic Kidney Disease (ADPKD). This disorder affects up to 1 in 500 individuals and is a significant cause of renal failure in the population. I am interested in identifying the molecular pathways that lead to the progression of this disease, and investigating potential therapies for this condition.
Publications
Bowden, S. A., Stockwell, P. A., Rodger, E. J., Parry, M. F., Eccles, M. R., Stayner, C., & Chatterjee, A. (2020). Extensive inter-cyst DNA methylation variation in autosomal dominant polycystic kidney disease revealed by genome scale sequencing. Frontiers in Genetics, 11, 348. doi: 10.3389/fgene.2020.00348
Macdonald, C. M., Kunnen, B., Stayner, C., & Eccles, M. R. (2019). Designing phantoms to accurately replicate circular depolarization in biological scattering media. Applied Optics, 58(35), 9577-9584. doi: 10.1364/AO.58.009577
Stayner, C., Brooke, D. G., Bates, M., & Eccles, M. R. (2019). Targeted therapies for autosomal dominant polycystic kidney disease. Current Medicinal Chemistry, 26(17), 3081-3102. doi: 10.2174/0929867325666180508095654
Bowden, S. A., Rodger, E. J., Bates, M., Chatterjee, A., Eccles, M. R., & Stayner, C. (2018). Genome-scale single nucleotide resolution analysis of DNA methylation in human autosomal dominant polycystic kidney disease. American Journal of Nephrology, 48(6), 415-424. doi: 10.1159/000494739
Kaur, G., Li, C. G., Chantry, A., Stayner, C., Horsfield, J., & Eccles, M. R. (2018). SMAD proteins directly suppress PAX2 transcription downstream of transforming growth factor-beta 1 (TGF-β1) signalling in renal cell carcinoma. Oncotarget, 9(42), 26852-26867. doi: 10.18632/oncotarget.25516
Journal - Research Article
Bowden, S. A., Stockwell, P. A., Rodger, E. J., Parry, M. F., Eccles, M. R., Stayner, C., & Chatterjee, A. (2020). Extensive inter-cyst DNA methylation variation in autosomal dominant polycystic kidney disease revealed by genome scale sequencing. Frontiers in Genetics, 11, 348. doi: 10.3389/fgene.2020.00348
Stayner, C., Brooke, D. G., Bates, M., & Eccles, M. R. (2019). Targeted therapies for autosomal dominant polycystic kidney disease. Current Medicinal Chemistry, 26(17), 3081-3102. doi: 10.2174/0929867325666180508095654
Macdonald, C. M., Kunnen, B., Stayner, C., & Eccles, M. R. (2019). Designing phantoms to accurately replicate circular depolarization in biological scattering media. Applied Optics, 58(35), 9577-9584. doi: 10.1364/AO.58.009577
de Bruin, W. E., Stayner, C., de Lange, M., & Taylor, R. W. (2018). Who are the key players involved with shaping public opinion and policies on obesity and diabetes in New Zealand? Nutrients, 10(11), 1592. doi: 10.3390/nu10111592
Bowden, S. A., Rodger, E. J., Bates, M., Chatterjee, A., Eccles, M. R., & Stayner, C. (2018). Genome-scale single nucleotide resolution analysis of DNA methylation in human autosomal dominant polycystic kidney disease. American Journal of Nephrology, 48(6), 415-424. doi: 10.1159/000494739
Kaur, G., Li, C. G., Chantry, A., Stayner, C., Horsfield, J., & Eccles, M. R. (2018). SMAD proteins directly suppress PAX2 transcription downstream of transforming growth factor-beta 1 (TGF-β1) signalling in renal cell carcinoma. Oncotarget, 9(42), 26852-26867. doi: 10.18632/oncotarget.25516
Stayner, C., Poole, C. A., McGlashan, S. R., Pilanthananond, M., Brauning, R., Markie, D., … Slobbe, L., … Parker, K., Wiles, A., … Leichter, A., Leask, M., … Jennings, M., Horsfield, J. A., Walker, R. J., & Eccles, M. R. (2017). An ovine hepatorenal fibrocystic model of a Meckel-like syndrome associated with dysmorphic primary cilia and TMEM67 mutations. Scientific Reports, 7, 1601. doi: 10.1038/s41598-017-01519-4
Pinnapureddy, A. R., Stayner, C., McEwan, J., Baddeley, O., Forman, J., & Eccles, M. R. (2015). Large animal models of rare genetic disorders: Sheep as phenotypically relevant models of human genetic disease. Orphanet Journal of Rare Diseases, 10, 107. doi: 10.1186/s13023-015-0327-5
Eccles, M. R., & Stayner, C. A. (2014). Polycystic kidney disease: Where gene dosage counts. F1000 Prime Reports, 6, 24. doi: 10.12703/p6-24
Ineson, J., Stayner, C., Hazlett, J., Slobbe, L., Robson, E., Legge, M., & Eccles, M. R. (2012). Somatic reactivation of expression of the silent maternal Mest allele and acquisition of normal reproductive behaviour in a colony of Peg1/Mest mutant mice. Journal of Reproduction & Development, 58(4), 490-500.
Stayner, C., Shields, J., Slobbe, L., Shillingford, J. M., Weimbs, T., & Eccles, M. R. (2012). Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: An investigation of the feasibility of renal cyst prevention in the foetus. Nephrology, 17(8), 739-747. doi: 10.1111/j.1440-1797.2012.01639.x
Stayner, C., Iglesias, D. M., Goodyer, P. R., Ellis, L., Germino, G., Zhou, J., & Eccles, M. R. (2006). Pax2 gene dosage influences cystogenesis in autosomal dominant polycystic kidney disease. Human Molecular Genetics, 15(24), 3520-3528.
